We used a canine intercalary bone defect model to determine the effects of recombinant human osteogenic protein 1 (rhOP-1) on allograft incorporation. The allograft was treated with an implant made up of rhOP-1 and type I collagen or with type I collagen alone.
Recombinant human osteogenic protein-1 (rhOP-1) is a member of the bone morphogenetic protein family of growth factors and is otherwise known as BMP-7. Recombinant human OP-1 and other BMPs are members of the transforming growth factor beta (TGF-β ) superfamily. 1 BMPs have been isolated from demineralised bone matrix and are implicated in the regulation of chemotaxis, mitosis and differentiation of bone progenitor cells. These molecules stimulate bone formation in rats and other mammalian models in vivo [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] as well as in human trials. 4 Additionally, delivery vehicles have the ability to augment the bone induction capabilities of BMPs. 10, [12] [13] [14] [15] [16] [17] [18] BMPs have been used clinically, 9, 19 including the healing of large bone defects after tumour excision in the treatment of osteolytic defects. Concern has been expressed with regards to the effect of BMPs on the remaining tumour cells but these concerns are, to some extent, assuaged by the inhibition of proliferation and differentiation of embryonic carcinoma cells by rhOP-1. 20 BMPs have been implicated as upregulators of osteoclastlike activity in vitro 6, [21] [22] [23] [24] and thus demonstrate the potential to upregulate bone remodelling in vivo . 6, 19, 25 Recombinant human OP-1 has been identified as one of the BMPs with the ability to initiate remodelling. 19, 21, 23, 26 Thus, BMPs are upregulators of coupled bone cell activity, inducing both resorption and deposition.
Structural bone allografts do not usually incorporate into the host completely, they demonstrate only superficial incorporation with marginal bone remodelling. Failure of allografts is alarmingly high, with long-term rates of fracture of up to 19%, nonunion of more than 18% and infection of 10%. 27, 28 The hypothesis of our study was that rhOP-1, applied to either the intramedullary or extracortical aspect of a bone allograft in the presence of a type I collagen carrier, would increase bone formation and healing of large bone allografts.
Materials and Methods
Surgical procedure. Sixteen adult mixed-breed dogs with a mean weight of 30 kg ( SD 3.2; 25 to 37) were used in the study. Each dog was given atropine intramuscularly (0.04 mg/kg; Boehringer Ingelheim Pharmaceuticals Inc., St Joseph, Missouri) and acepromazine intramuscularly (0.04 mg/kg) as anaesthetic premedication. General anaesthesia was induced by intravenous administration of thiopental (17.5 mg/kg) and maintained by halothane and oxygen inhalation after endotracheal intubation. The animals were also given a prophylactic intramuscular injection of cephazolin antibiotic (1.0 g) before surgery, at the completion of surgery, and 12 hours post-surgery.
Through a lateral approach a 4 cm segment was resected from the mid-diaphysis of the femur after plating of the bone. The defect was treated using a matching 4 cm allograft obtained from another dog.
The allografts were debrided of all soft tissues and rinsed in normal saline. An implant consisting of recombinant osteogenic protein-1 (rhOP-1, Stryker Biotech, Boston, Massachusetts) with a bovinebone-derived type I collagen putty (Stryker Biotech) was applied to one limb (rhOP-1 treated side) and an implant with only type I collagen putty was applied to the other limb (control side).
An eight-hole plate was fixed laterally using four bicortical screws. The screws were then loosened and an osteotomy was performed. The allografts were placed in the defects and fixed with screws. A seven-hole plate was fixed anterior to both host and allograft. The muscular fascia and subcutaneous local soft tissues were then closed over the bone with interrupted 2-0 sutures, and 2-0 sutures were used to close the skin. Buprenorphine (Buprenex; Reckitt and Colman Pharmaceutical Inc., Richmond, Virginia) was routinely given to control post-operative pain during the first 24 hours after surgery (0.02 mg/kg), and then as needed for the next 24 hours. The surgical wound was observed daily for evidence of infection or dehiscence. The animals were allowed to weight-bear as soon as tolerated. The protocol was approved by the Institutional Animal Care and Use Committee.
All animals were killed at 12 weeks and the grafted segments were removed, wrapped in sterile gauze, and frozen at -80˚C for at least three days between procedures. The allografts were not immunologically tested. Load-bearing. This was measured before surgery and at 3, 6, 9 and 12 weeks post-operatively. Load-bearing was measured using a dynamic force plate (Advanced Mechanical Technology, Watertown, Massachusetts) recessed into a carpeted runway, with a minimal approach distance of 4 m and at a constant velocity to ensure establishment of a consistent gait. An observer recorded each successful footstrike, which was defined as the complete contact of the hind foot. A minimum of six successful runs was obtained for each hindlimb. For statistical analysis between groups and between control and treatment sides within the same group, the results were normalised using the appropriate pre-operative values. Radiographic analysis. Radiographs were taken under sedation with intramuscular ketamine (8 mg/kg), and xylazine (0.8 mg/kg) before surgery to avoid anatomical variation and to confirm closure of the epiphyseal plates. Radiographs were also taken at 2, 4, 6, 8, 10 and 12 weeks postoperatively to monitor periosteal callus formation. The area of periosteal callus was measured directly on anteroposterior and mediolateral radiographs using an image analysis software package (Bioquant System IV; R & M Biometrics Inc., Nashville, Tennessee) and a sonic digitiser (Summa Sketch II Plus; Summagraphics, Seymour, Connecticut). Callus measurements were recorded around the allograft and for 1 cm over the recipient femur. The area of periosteal callus was averaged for the two planes. Biomechanical testing. The allograft was cut transversely to include 1 cm of the host bone. The proximal halves were embedded in hollow aluminium blocks up to a level of 12.5 mm from the bone ends using Wood's metal (Cerro Metal Product Co., Bellefonte, Pennsylvania) and augmented with the distal and proximal locking pins. An axial torsion test at a strain rate of 15˚/min was performed on both femora using a mechanical testing machine (MTS Bionix 858; MTS, Edin Prairie, Minnesota). The slope of the initial linear portion of the curve determined torsional stiffness. Ultimate strength was defined during testing as the maximal torque applied to failure. Histological and histomorphometric analysis. The distal halves of the donor bone were prepared for undecalcified histological analysis. The specimens were fixed in 70% ethanol solution, dehydrated in increasing concentrations of ethanol, defatted in acetone, and embedded in polymethylmethacrylate (Technovit 9100; Kulzer GmbH, Wehrheim, Germany). Longitudinal and transverse sections were cut with a thickness of approximately 250 µ m and ground to a thickness of 80 µ m.
The longitudinal sections were surface stained with toluidine blue O and basic fuchsin complex (No. 08824; Polysciences Inc., Warrington, Pennsylviania). The longitudinal sections were evaluated for areas of new bone, cartilage and fibrous tissue using the semi-automated image analysis software package (Bioquant System IV; R & M Biometrics Inc).
Contact microradiographs were made using a high-resolution film (Industrex SR, Kodak-Industriem, Challon sur Saune, France) exposed at 35 kVp and 3 mA for 45 seconds in a self-contained radiographic cabinet (Faxitron X-ray Corp., Buffalo Grove, Illinois). A target-to-specimen distance of 20 cm was used during exposure of the radiographs. The films were developed for three minutes in a Kodak film developer (Model D-19 Developer, Eastman Kodak, Rochester, New York). The transverse section slides were evaluated for porosity, mineral apposition rate and osteon density. Mineral apposition rate in the cortical bone area was measured using a double labelling technique. Animals were given intravenous injections of bone labels two weeks (Calcein blue, 30 mg/kg) and one week (Alizarin red, 30 mg/kg) before being killed.
Labelled osteon density, the number of single or double fluorochrome-labelled osteons per unit area in a given section, was measured using sections mounted on microscope slides and illuminated using an ultraviolet light source. Labelled osteons were counted and the specimen area was measured using the image analysis software package (Bioquant System IV, R & M Biometrics Inc). The total number of labelled osteons was divided by the specimen area as previously described by Sorensen, Bretlau and Jorgensen. 29 Bone mineral appositional rates were determined after selection of all double-labelled osteons in the transverse sections using fluorescent microscopy and the same histomorphometric software. The inter-label distance was measured in at least four locations for each osteon and the mean was divided by the labelling interval time to derive the mineral appositional rate. Values of the mineral apposition rate for the two sections in the allograft or host bone were aver-aged. Allograft and host bone porosity were determined using digitised images of contact microradiographs and custom software 30 on a workstation (Iris Indigo Elan, SiliconGraphics, Mountain View, California). Statistical analysis. Mechanical testing and histological data were collected in a blinded fashion, with the source of the sample unknown to the evaluator. Paired data from the treatment and control sides were compared using a paired Student's t -test. Data between groups were analysed using an unpaired Student's t -test. Time-repeated data, such as gait and callus area measurements, were analysed with analysis of variance and Tukey's post-hoc test. A difference was considered significant when p values were less than 0.05.
Results
Complications. Two dogs had nonunion at the allograft host junction on the untreated control side, which were obvious upon removal of the plate. We elected not to include these animals in the biomechanical analysis. These nonunions represent decreased healing in the absence of rhOP-1 but we have chosen to consider these nonunions as a complication and feel it is more informative to show that even without the inclusion of these two failures to heal in the absence of rhOP-1 there are still significant increases in the biomechanical indices measured with rhOP-1 treatment. Radiographic analysis (Table I ) . In the intramedullary group, the area of the periosteal callus was significantly higher on * two dogs were excluded from the analysis because of fibrous unions on the control side. p < 0.03 compared with the control side † p < 0.03 compared with the control side ‡ p < 0.005 compared with the control side the rhOP-1 treated side at 4, 6, 8, 10, and 12 weeks following surgery. In the extracortical group, the periosteal callus area was significantly higher on the rhOP-1 treated side at 2, 4, 6, 8, 10, and 12 weeks following surgery. In this group, the callus area reached its maximum values at four weeks after surgery and decreased with time thereafter. The periosteal callus area on the rhOP-1 treated side in the extracortical group was significantly higher than that in the intramedullary group at 2, 4 and 6 weeks after surgery. Load-bearing (Table II ) . In the intramedullary group, there was no significant difference between those treated with rhOP-1 and the controls. In the extracortical group, loadbearing was significantly higher in the rhOP-1 treated side at 6 and 9 weeks after surgery (p < 0.03 and p < 0.05, respectively). There was no difference between the intramedullary and extracortical groups at any time.
Mechanical testing (Table III) . In both the intramedullary and the extracortical groups, the torsional stiffness was significantly higher on the rhOP-1 treated side than the control (p < 0.03). The maximum torque was significantly higher on the treated side than on the control side in both the intramedullary and extracortical groups (p < 0.03 and p < 0.005, respectively). The intramedullary and extracortical groups appeared to have similar mechanical properties.
Histomorphometric analysis
Tissue composition (Table IV) . There was no significant difference in tissue composition of the new bone, cartilage, and fibrous tissue areas between control and treatment sides at the allograft-host bone junction in the both groups (p = 0.10, 0.35 and 0.18, respectively in the intramedullary group and p = 0.31, 0.21, and 0.14, respectively in the extracortical groups). There was also no significant difference in tissue composition of the new bone, cartilage, and fibrous tissue areas between the intramedullary and extracortical groups (p = 0.97, 0.33, and 0.33, respectively). Porosity (Table V) . The treated side was significantly more porous than the control side in the intramedullary group (p < 0.03) indicating more bone resorption, but no difference was detected in the extracortical group. Differences in porosity between intramedullary and extracortical groups were not significant. Mineral apposition rate (Table V ) . In the intramedullary group, the allograft and host bones on the treated side had a significantly higher mineral apposition rate than the control side (p < 0.03 and p < 0.005, respectively). Only the host bone on the treated side in the extracortical group had a significantly increased mineral apposition rate compared with the control side (p < 0.0005). No statistical difference was observed between the intramedullary and extracortical groups.
Active osteon density (Table V) . The density of active osteons in the allografts was significantly higher in the treated side compared with the controls in both the intramedullary (p < 0.03) and extracortical groups (p < 0.005). No significant difference was observed between the control and treated sides in the adjacent host bone in either group. In addition, there was no significant difference in osteon density between the intramedullary and extracortical groups.
Discussion
The hypothesis of our study was that rhOP-1, applied to either the intramedullary or extracortical aspect of a bone allograft in the presence of a type I collagen carrier, would increase bone formation and healing of large bone allografts.
The results indicate that bone allografts treated with rhOP-1 and a type I collagen carrier have superior healing in terms of torsional stiffness, maximum torque, and periosteal callus compared with control allografts. Furthermore, it appears that when rhOP-1 and type I collagen are delivered extracortically there is more bone formation extracortically, as evidenced by more periosteal callus, than when they are delivered in the medullary canal. However, the periosteal callus may not reflect intramedullary bone formation. Further evidence of the increased healing in the presence of rhOP-1 compared with the control group is implicated by the two nonunions in the control group compared with no nonunions in the rhOP-1 treated group. The nonunions in the control group were excluded from the biomechanical analysis as it was thought that they might be complications which would show a misleading difference between the treatment and control groups. Obviously had these two nonunions been analysed the rhOP-1 healing compared with the controls would have been even more significant. rhOP-1 has been shown to increase bone formation in large bone defects in the presence of non-structural allografts 9 and rhBMP-2 induced a stronger union at host bone allograft junctions in the presence of a collagen sponge. 11, 31 However, the effects of rhOP-1 on remodelling of structural bone allografts in the presence of type I collagen have not been studied. Currently, one method of reconstruction after bone tumour resection involves the use of these structural allografts with plate and screw fixation. 28 Furthermore, in our model we can compare bone formation in the intramedullary and extracortical aspect of the allograft because the plate and screws allow for intramedullary bone formation as opposed to the intramedullary rod fixation described by other investigators. 11, 31 Clearly, various BMPs and carriers need to be studied in greater detail to delineate the most effective method for the healing of large bone defects with structural allografts.
There have been numerous concerns about the safety of growth and differentiation factors such as rhOP-1 in the setting of a tumour resection in which there may still be tumour cells present, as in a wide contaminated resection margin of a sarcoma, or in the treatment of metastatic disease. However, Maliakal et al 32 showed that rhOP-1 inhibited proliferation of rat osteosarcoma (17/2.8) cells. Lietman et al 26 showed that rhOP-1 (in porcine cartilage explants) increased proteoglycan synthesis but did not dramatically change the size of the proteoglycan monomers, their ability to form aggregates with hyaluronic acid, or the ratio of chondroitin 4-sulphate to chondroitin 6-sulphate glycosaminoglycans; indicating that apparently the same cellular processes (not aberrant ones which suggest dedifferentiation) were present before and after rhOP-1 stimulation. Andrews et al 20 further showed inhibition of proliferation and induction of differentiation of pluripotent human embryonal carcinoma cells by rhOP-1. Thus in these separate studies, rhOP-1 actually seemed to differentiate rather than cause the induction or proliferation of cancer cells that was feared. 20, 32 Recently there has been substantial evidence to suggest that transdifferentiation from epithelial to mesenchymal cells is an integral part of the process of metastatic disease to bone from primary carcinomas such as breast cancer and that this transdifferentiation is induced by activation of the TGF-β1 receptor. There has thus been concern that rhOP-1, as a member of the TGF-β superfamily, could transdifferentiate cells. However, in mouse NMuMG breast epithelial tumour cells, rhOP-1 did not cause transdifferentiation although this transdifferentiation was induced by activation of the TGF-β1 receptor. 33 The current study does not demonstrate a significant difference between the intramedullary and extramedullary application of the rhOP-1 implant. When the rhOP-1 type I collagen implant was placed in the intramedullary aspect of the allograft the porosity and mineral apposition rate within the allograft was more significant and therefore suggestive of more allograft bone remodelling. On the other hand when the same implant was placed in the extramedullary aspect there was a greater significance of periosteal new bone formation and an earlier functional recovery. Although the intramedullary and extramedullary groups did not differ significantly in an unpaired t-test in these measures it is possible that if compared in a bilateral study, or with higher numbers of animals, there could be a difference in healing mechanism between the two groups. Such a difference could be explained by the difference in dispersal of the rhOP-1 implant between the two groups. In other words, when the implant is placed in the intramedullary aspect of the allograft, the rhOP-1 dose could be more sustained in the confined area of the inside of the allograft and this dose pattern could lead to greater allograft remodelling. Whereas, when the same implant is placed in an extramedullary position the rhOP-1 dose could be more immediate and ephemeral as the rhOP-1 is more readily accessible and easily integrated into the animal's autologous general body fluids. Indeed, in the rat subcutaneous model [34] [35] [36] [37] one of the authors (SAL) has also noted more ectopic bone formation in the presence of a one-time dose of rhOP-1 in the presence of type I collagen compared with a more sustained release with the same type I collagen. 38 Further investigation is required to see if the method of application or dosing frequency of rhOP-1 has a differential effect on bone formation in a large animal model.
In this study we describe a significant effect with an rhOP-1 implant on allograft healing when applied either in an intramedullary or extramedullary position. We feel that the rhOP-1 implant should be considered after resection of primary tumours and even in the treatment of bone defects in metastatic disease.
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